Supreme Court To Consider Patent Use Codes, But At Best Can Give Generic Firms A Hunting License
This article was originally published in The Pink Sheet Daily
The Supreme Court will address whether an ANDA sponsor can challenge a brand name company's alteration of a drug's patent use code to block generic competition.
You may also be interested in...
Court to decide whether sales reps qualify for overtime pay in case involving former GlaxoSmithKline reps; it is the third pharma case this term.
In calling for the Supreme Court to take up a case involving the alteration of a patent use code to block generic competition, the Acting Solicitor General suggested steps FDA could take to address the problem.
Patent Code Changes: Dangerous Precedent Or Unique Circumstance? Supreme Court Seeks Government's Views
Generic companies contend that the Caraco v. Novo Nordisk case could enable brand firms to game the system and delay generic approvals; Novo says the case may never happen again.